基于专利法对药品增量创新之评价研究  

Reasonable Evaluation of the Pharmaceutical Incremental Innovation in Patent Law

作　　者：赵歆[1] 

机构地区：[1]同济大学法学院,上海200092

出　　处：《科技管理研究》2015年第17期151-155,共5页Science and Technology Management Research

基　　金：国家社会科学基金重大项目"促进自主创新能力建设的国家知识产权政策体系研究"(12&ZD073);国家知识产权局专利保护重点联系机制工作项目"专利侵权损害赔偿制度研究"(20121029952)

摘　　要：目的为在专利法框架下对药品专利增量创新之现象予以评价。分析药品专利增量创新的定义、特征、产生动因与已有实证研究,论述有关药品专利增量创新的争论及其在TRIPS协议与国内专利法中的合法性评价。研究认为,考虑到制药产业涉及收回药物研发成本与平衡患者近药权等公共健康问题,应正确看待药品专利增量创新,在承认其价值的同时,从有利于我国原研药企创新发展的角度出发设置宽严适中的药品可专利性判断标准。For the purpose of evaluating the pharmaceutical incremental innovation in patent law, this article first analyzes the definition, characteristics, causes and empirical studies of pharmaceutical incremental innovation. Then it discusses the legality of pharmaceutical incremental innovation under TRIPS and national patent laws, and finally concludes that considering the recoup of R＆D in pharmaceutical industry and patients＇ accessibility of drugs with reasonable price, the pharmaceutical incremental innovation deserves fair treatment; from the perspective of encouraging China＇ s brand name drug manufacturers, proper criterion of patentability for incremental drugs should be established.

关 键 词：药品 增量创新 专利法 可专利性 

分 类 号：R95[医药卫生—药学] D923.42[政治法律—民商法学]